Kornimate/medical-research-clean huggingface dataset:
breast cancer long-term outcomes on cardiac functioning: a longitudinal study

Conditions: Neoplasm, Breast; Heart Failure; Cardiotoxicity; Ventricular Dysfunction

Summary: rationale: in addition to surgery, effective breast cancer (bc) treatment typically requires chemotherapy, radiotherapy, or both. however, it is still unclear whether patients with bc are at increased risk of long-term cardiac dysfunction due to the adverse effects of these therapies. in a cross-sectional study in primary care, a comparison on cardiac dysfunction between 350 bc survivors and 350 age- and general practitioner (gp)- matched controls without cancer was made. in that study, bc survivors were at increased risk of mild systolic cardiac dysfunction (left ventricle ejection fraction (lvef)\< 54%). by contrast, there was no significant difference in an lvef \< 50% or in diastolic dysfunction. to date it remains uncertain whether the mild or subclinical dysfunction we observed predicts further cardiac deterioration. consequently, the translation of these results into guidelines for the daily practice of the gp is unclear. objective: the aim of the here proposed study is to clarify whether cardiac function in survivors of bc should be monitored by gps, by assessing whether an unselected population of long-term bc survivors is at increased risk of developing cardiac dysfunction, whether in this group at-risk subgroups exists, and what factors are associated with the highest risk. study design: a new assessment of cardiac function among women included in the bloc-i study. this produces a longitudinal matched cohort design consisting of two cohorts in primary care. study population: survivors of bc, diagnosed ≥11 years ago who received chemotherapy and/or radiotherapy, and a matched reference population with no history of cancer. all participants participated in the breast cancer long-term outcome of cardiac function (bloc-i) study. main study parameters/endpoints: left ventricular systolic dysfunction. systolic cardiac dysfunction is defined as a lvef \<54/50/45%.


Eligibility criteria:
inclusion criteria: * patients who previously took part in de bloc-i study will be included. these criteria were: * females diagnosed with stage i-iii bc at least five years ago or local or locoregional recurrence of bc at least five years ago * treatment with chemotherapy and/or radiotherapy. exclusion criteria: * patients unfit to travel to the hospital due to severe mental or physical illness, based on assessment by their gp. exclusion criteria for the bc survivors in the bloc-i study were: * metastatic disease at the time of bc diagnosis; * bc treatment after 80 years of age; * history of treatment for other types of cancer.

Keywords: breast cancer cardiotoxicity heart failure
eus guided celiac neurolysis

Conditions: Pancreatic Cancer Pain

Summary: * hypothesis: - direct cgn enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma. * rationale: * standard cpn leads to inaccurate delivery of the injectate with rapid dispersal thereby only briefly remaining in contact with neural structures and limiting the degree of neurolysis. poor targeting and delivery of a neurolytic agent may result in diminished neurolysis and decrease efficacy.


Eligibility criteria:
inclusion criteria: * 1. unresectable pancreatic carcinoma (t4 or m1) or advanced t3 disease * 2. cytologic or histologic confirmation of pancreatic carcinoma * 3. abdominal pain (≥ 3 on nrs scale), ≥ 2 days/week, lasting ≥ 1 hour/ day, stable intensity for ≥ 7 days * 4. eus clinically indicated (for non-study purposes) exclusion criteria: * 1. uncorrectable coagulopathy: (inr) \> 1.5 and/or platelets \< 50,000 * 2. abdominal surgery within 1 month * 3. prior celiac plexus or ganglia neurolysis. * 4. initiation or modification in chemotherapy or radiotherapy within prior 7 days. * 5. direct tumor infiltration of the celiac trunk and/or celiac ganglia.

Keywords: pancreatic cancer pancreas cancer pain celiac plexus neurolysis
opals critical care sub-studies

Conditions: Cardiac Arrest

Summary: the purpose of the study is to evaluate the incremental benefit of a full advanced life support ems program on the outcomes of chest pain, respiratory and major trauma patients.


Eligibility criteria:
inclusion criteria: * chest pain sub-study: adult patients with a complaint of chest pain of an acute nature transported to hospital by ambulance. patients with a complaint of pain in arms, neck or jaw if consistent with myocardial ischemia. patients must have an ambulance return code of prompt, urgent, or no patient carried. * respiratory sub-study: adult patients with a chief complaint of shortness of breath defined as acr codes of respiratory failure, shortness of breath nyd, pulmonary edema (chf), asthma and had either prehospital assisted ventilation or abnormal respiratory rates (\&gt;=24 or \&lt;=10) * major trauma sub-study: adult patients who have suffered an injury from any mechanism with an injury severity score of \&gt;12 who have been transported to hospital by land ambulance, and who have been entered into the ontario trauma registry (otr) comprehensive data set. exclusion criteria: * all sub-studies: * patients under the age of 16 * patients who are vital signs absent prior to ems arrival. * chest pain sub-study: * patients suffering primarily from respiratory distress, respiratory failure, pulmonary edema, asthma, palpitations or epigastric pain. pain

Keywords: chest pain, shortness of breath, injury, trauma
prophylactic ketorolac post epiretinal membrane surgery

Conditions: Macular Edema

Summary: evaluate the efficacy of ketorolac 0.5%, a topical non-steroidal anti-inflammatory drug (nsaid), to prevent macular edema after epiretinal membrane surgery. patients undergoing epiretinal membrane surgery have increased risk of macular swelling which can adversely affect vision. since post-intraocular surgery inflammation is a contributing factor to macular swelling and loss of vision, nsaid drops may be able to prevent or minimize the deleterious effects of macular swelling after epiretinal membrane surgery.


Eligibility criteria:
inclusion criteria: * idiopathic epiretinal membrane diagnosis requiring membrane peel surgery exclusion criteria: * proliferative diabetic retinopathy * sickle cell retinopathy * radiation retinopathy * choroidal folds * hypersensitivity or allergy to nsaids * wet macular degeneration * branch retinal vein occlusion (brvo) * central retinal vein occlusion (crvo) * complicated membrane peel surgery

Keywords: epiretinal membrane
education vs education plus intervention in hiv/hcv diagnosis (drive 03)

Conditions: HIV Infection; HCV Coinfection

Summary: objectives: a targeted hiv testing strategy (tts) through an hiv risk of exposure and indicator conditions (re\&ic) questionnaire resulted in same rate of new hiv infection diagnosis (nhid), coverage and even reduced costs compared with a universal non targeted (non tss) hiv testing strategy in a prior study (drive 01). to compare number of new hiv/hcv infection diagnoses (nhid hiv/hcv) and costs two hiv/hcv testing programs in the primary health care: an educational and support only initiative to enhance hiv /hcv testing (edsup) or edsup plus a resourced external program (drive 03). methodology: prospective, randomized 1:1, clustered, crossover study, in one health care area of madrid, spain, comparing the implementation of two hiv testing programs, edsup only vs. edsup plus drive 03 program in 4 primary care centers (pcc´s). people randomized to edsup plus drive 03 program, non hiv infected, between 18-65 years, attending to any of the 4 pcc´s, not previously included in the study will be offered to participate. hiv testing program will be evaluated by measuring absolute number of new diagnosed infections (ndi) hiv/hcv and costs. other outcomes considered will be people assigned and offered to participate, number of hiv tests performed, coverage (hiv /hcv tests/assigned population ratio), and rate of ndi hiv/hcv per ‰ tests performed. six months prior to randomization main outcome variables will be recorded in the 4 ppc´s. before randomization, edsup will be equally implemented in the 4 pcc´s. after randomization, first six months, drive 03 program will be implemented in 2 pcc´s and in the other 2 observation of interest variables will be conducted. after first 6 month study period, pcc´s will be crossover to the opposite arm of randomization. drive 03 program will offer rapid hiv tests, and testing staff to conduct all study procedures. for ndi hiv/hcv, molecular epidemiology, delayed diagnosis, retention in care, hiv/hcv treatment and control/eradication will be also monitored.


Eligibility criteria:
inclusion criteria: * have attended to one of the pcc´s randomized to drive 03 hiv testing program, * be 18-70 years * have understood, accept and sign the written informed consent, and in case of inability, it will be signed by the legal representative. exclusion criteria: * a prior hiv diagnosis, * have already been included in the drive 03 study, * inability to understand the spanish language.

Keywords: hiv testing program hcv testing program education
evaluation of the biocompatibility of cartridge blood set versus standard blood line

Conditions: Chronic Kidney Failure

Summary: the primary objective is to collect data to evaluate the biocompatibility of two types of blood circuit, already on the market.

interactions between blood components (cells and proteins) and the extracorporeal circuit induce the activation of several biological systems such as platelets, complement and coagulation cascades. the coagulation system generates a key enzyme, factor iia or thrombin, responsible for blood clotting in the dialysis circuit because clotting in the circuit may reduce the dialysis efficiency, the anticoagulation of the extracorporeal circuit is needed . for several years, most of the researches were mainly focused on the improvement of the biocompatibility of dialysis membranes . the contribution of the various components of the dialysis circuit on the coagulation activation has not been clearly established. a circuit integrating a cartridge blood set is commercialised for several years. the design of this cartridge blood set reduces the surface in contact with blood and minimizes the blood air interface which are well known sources of coagulation activation. the aim of this study is to collect data to evaluate the biocompatibility of two types of blood circuit (cartridge blood set vs standard blood line).

Eligibility criteria:
inclusion criteria: * patients suffering from chronic renal failure, * patients treated in hd performed with or without heparin injection in the extra corporeal circuit (ecc) irrespective the type of heparin (ufh and lmwh), * patients treated three times a week for a minimum of three (3) months, * patients 18 years or older, * patients with a well-functioning vascular access as judged by the investigator, * patients with negative serologies (hiv, hepatitis), * patients having signed written informed consent to participate in the study. exclusion criteria: * patients with known allergy to heparin, * patients with acute inflammatory event that may affect, as judged by the investigator, the results of the study or the safety of the patients, * active malignant disease, * pregnant women, nursing mothers and women planning a pregnancy during the course of the study, * patients under guardianship, * patients participating in other studies that could interfere with the objectives of this study, * patients treated in single needle mode, * patients with catheter, * patients receiving anti-vit k drug.

Keywords: chronic kidney failure hemodialysis biocompatibility
prevalence of alzheimer's disease pathology in the community

Conditions: Dementia of Alzheimer Type; Alzheimer Disease; Mild Cognitive Impairment; Pathology; Biomarker in Early Diagnosis

Summary: the goal of this observational study is to (i) study the proportion of people with alzheimer's disease pathology in a large norwegian population-based cohort of people aged 70 years or older and to (ii) study longitudinal changes of alzheimer's disease pathology in the same population over a 14 year period. the main aims are: * what is the proportion of people with alzheimer's disease pathology, defined by elevated plasma p-tau217, in a large norwegian population-based cohort of people aged 70 years or older. * what is the proportion of people with alzheimer's disease pathology, defined by elevated plasma p-tau217, among those with normal cognition, mild cognitive impairment and dementia in a large norwegian population-based cohort of people aged 70 years or older. * what is the association between plasma p-tau217 concentration and mild cognitive impairment or dementia 4, 10 and 14 years later, respectively. * what is the association between plasma nfl concentration and mild cognitive impairment or dementia 4, 10 and 14 years later, respectively. data is used from the nord-trøndelag health study (hunt) wave 3 (2006-2008) and 4 (2017 - 2019, also including hunt ait 2021-2023).


Eligibility criteria:
inclusion criteria: * living in the area of nord-trøndelag, where the hunt study is carried out. * age 70 or older when participating in hunt4 * available blood sample from hunt3, hunt4 70+ or hunt4 70+ ait exclusion criteria: * none

Keywords: blood-based markers population-based p-tau217 cross-sectional longitudinal nfl alzheimer's disease pathology
suprachoroidal triamcinolone versus posterior subtenon triamcinolone alone or formulated in the management of diabetic macular edema.

Conditions: Diabetic Macular Edema of Left Eye

Summary: background retinal vascular disorders, such as diabetic retinopathy, hypertensive retinopathy, retinal hemorrhage, and retinal vein occlusion are significant causes of vision impairment and blindness worldwide. diabetic retinopathy (dr) is the most common retinal vascular disorder and is the leading cause of vision loss among patients aged 25 to 74 years. aim to compare formulated posterior subtenon triamcinolone acetonide (psta) injection versus posterior subtenon triamcinolone acetonide alone versus suprachoroidal triamcinolone in the management of diabetic macular edema.


Eligibility criteria:
inclusion criteria: * diminution of vision due to diabetic macular edema. * cmt ≥ 250 µ. * willing to participate in the study. exclusion criteria: * unwilling to participate in the study, 2) * ischemic rvo, * previous laser treatment * glaucoma, macular ischemia, cataract, vitreous hemorrhage, and neovascularization of the iris, * patients with previous anti vegfs or steroid injections or any eye surgery three months before the inclusion, * cardiac co-morbidities result in significant hemodynamic changes, 7)respiratory diseases need treatment with antibiotics, * suffering from other chronic diseases as diabetes, * patient with allergy from triamcinolone acetonide.
multiple fields radiotherapy versus intravenous rituximab in the treatment of indolent cutaneous lymphomas b-cell with multiple or recurrent lesions

Conditions: Indolent Cutaneous B Cell Lymphomas

Summary: cutaneous lymphomas are the most frequent extranodal lymphomas after digestive lymphomas. a quarter are b-cell lymphomas. 80% of cutaneous b cell lymphomas are indolent cutaneous b cell lymphomas. these indolent cutaneous b cell lymphomas are characterized by good prognosis (survival rate at 5 years: 90%), but also by the frequency of cutaneous recurrences. the radiotherapy is currently the most widely used treatment, with complete response rate close to 100% for a lesion treated. however, it has limits when there are outset multiple lesions inaccessible to a single radiotherapy field (concerning one case in three), or during recurrences. in these situations, conventional chemotherapy is not recommended and multi-field radiotherapy is often used empirically, but its effectiveness has never been studied prospectively. recently, retrospective studies with small numbers patients (totaling sixty patients) reported complete response rates of 80 to 100% with rituximab (anti-cluster of differentiation antigen 20 (cd20) antibodies) used as monotherapy in non-standardized treatment by intravenous with a recurrence rate of less than one case in three. these data suggest that rituximab by intravenous with a standardized initial cycle followed by a maintenance therapy could improve the prognosis of indolent cutaneous b cell lymphomas with multiple lesions or of recurrent lesions.

compare the efficacy and safety of two treatment strategies for indolent cutaneous b cell lymphomas with multiple or recurrent lesions: rituximab by intravenous versus multi-field radiotherapy.

Eligibility criteria:
inclusion criteria: * patients with histological diagnosis of indolent cutaneous b cell lymphomas * patients with multiple lesions inaccessible to a single field of radiotherapy or patients with a recurrence outside the field of first radiotherapy * patient with a lesion of at least 15 mm in major axis and a total tumor surface area greater or egal than 4 cm2 * patient with a negative staging * patient consenting to participate to the study * patient enrolled in the national healthcare insurance program * patient older than 18 years exclusion criteria: * contraindication for rituximab or radiotherapy * immunosuppressive therapy * immunosuppression
escalating doses of pm01183 in combination with gemcitabine in patients with specific unresectable solid tumors

Conditions: Specific Advanced Solid Tumors

Summary: phase i multicenter, open-label, clinical and pharmacokinetic study of pm01183 in combination with gemcitabine in non-heavily pretreated patients with selected advanced solid tumors to determine the maximum tolerated dose (mtd) and the recommended dose (rd) of pm01183 in combination with gemcitabine, to characterize the safety profile and feasibility of this combination in patients with selected advanced solid tumors, to characterize the pharmacokinetics (pk), to obtain preliminary information on the clinical antitumor activity in non-heavily pretreated selected solid tumor patients and to evaluate the pharmacogenomics (pgx) in tumor samples of patients exposed, in order to assess potential markers of response and/or resistance.


Eligibility criteria:
inclusion criteria: * voluntarily written informed consent * age: between 18 and 75 years (both inclusive) * eastern cooperative oncology group (ecog) performance status (ps) ≤ 1 * life expectancy ≥ 3 months * patients with a histologically/cytologically confirmed diagnosis of advanced disease of any of the following tumors: 1. breast cancer 2. epithelial ovarian cancer (including primary peritoneal disease and/or fallopian tube carcinomas and/or endometrial adenocarcinomas) 3. stromal uterine sarcomas 4. non-small cell lung cancer (nsclc) 5. platinum-refractory or relapsed germ cell tumors 6. adenocarcinoma of the exocrine pancreas 7. biliary tract adenocarcinoma 8. adenocarcinoma or carcinoma of unknown primary site 9. advanced or unresectable mesothelioma * at least three weeks since the last anticancer therapy,including radiation therapy (rt) * adequate bone marrow, renal, hepatic, and metabolic function * left ventricular ejection fraction (lvef) by echocardiography (echo) or multiple-gated acquisition (muga) within normal range (according to institutional standards). * women of childbearing potential must have a negative serum pregnancy test before study entry. both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six weeks after discontinuation of treatment. exclusion criteria: * concomitant diseases/conditions: * history or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year. * symptomatic or any uncontrolled arrhythmia * ongoing chronic alcohol consumption, or cirrhosis * active uncontrolled infection. * known human immunodeficiency virus (hiv) infection. * any other major illness that, in the investigator's judgment * brain metastases or leptomeningeal disease involvement * men or women of childbearing potential who are not using an effective method of contraception * patients who have had radiation therapy in more than 35% of the bone marrow * history of previous bone marrow and/or stem cell transplantation * prior treatment with gemcitabine-containing therapy for advanced disease

Keywords: lurbinectedin pm01183 tumors cancer pharma mar
a study of gfh925 in combination with cetuximab in previously untreated advanced nsclc harboring kras g12c mutation

Conditions: Advance Non-small Cell Lung Cancer

Summary: this is a phase ib/ii study. the objectives are to evaluate the safety/tolerability and efficacy of gfh925 in combination with cetuximab in advanced kras g12c mutant nsclc, to characterize pharmacokinetics (pk) of gfh925 in combination with cetuximab in advanced kras g12c mutant nsclc


Eligibility criteria:
inclusion criteria: 1. patient has provided informed consent form (icf). 2. males or females aged ≥ 18 years. 3. eastern cooperative oncology group (ecog) performance status of 0\~1. 4. life expectancy \> 3 months judged by the investigator. 5. have histologically or cytologically confirmed advanced kras g12c-mutated nsclc. 6. have at least one measurable lesion per recist 1.1. 7. have sufficient organ functions. 8. with toxicities left from prior anti-tumor therapy resolved to baseline or ctcae grade 1 (neurotoxicity or alopecia ≤ grade 2). 9. women of childbearing potential (wocbp) and male patients with wocbp partners must agree to use effective contraception method during the study specified period. exclusion criteria: 1. with clinically significant cardiovascular diseases. 2. with active central nervous system (cns) metastases and/or carcinomatous meningitis. 3. with clinically significant gastrointestinal diseases. 4. with active infections. 5. with uncontrollable or symptomatic pleural effusion, ascites, or pericardial effusion. 6. with uncontrolled systemic diseases, such as hypertension or diabetes. 7. prior treatment with an inhibitor specific to kras g12c. 8. major surgery within 4 weeks prior to initiation of study treatment. 9. with known allergies to the study drugs or components. 10. pregnant or lactating females, or female patients intend to become pregnant during participation.